Defining regional infusion treatment strategies for extremity melanoma

Comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents

Yasunori Yoshimoto, Christina K. Augustine, Jin S. Yoo, Patricia A. Zipfel, M. Angelica Selim, Scott K. Pruitt, Henry S. Friedman, Francis Ali-Osman, Douglas Tyler

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Five different human melanoma xenografts were used in a xenograft model of extremity melanoma to evaluate the variability of tumor response to regionally administered melphalan or temozolomide and to determine if various components of pertinent drug resistance pathways for melphalan [glutathione S-transferase (GST)/glutathione] and temozolomide [O6-alkylguanine DNA alkyltranferase (AGT)/mismatch repair (MMR)] could be predictive of tumor response. Xenograft-bearing rats underwent regional isolated limb infusion with either melphalan (90 mg/kg) or temozolomide (2,000 mg/kg). The levels of AGT activity, GST activity, glutathione level, and GST/AGT expression were examined in this group of xenografts and found to be quite heterogeneous. No correlation was identified between melphalan sensitivity and the GST/glutathione cellular detoxification pathway. In contrast, a strong correlation between the levels of AGT activity and percentage increase in tumor volume on day 30 (r =0.88) was noted for tumors treated with temozolomide. Regional therapy with temozolomide was more effective when compared with melphalan for the xenograft with the lowest AGT activity, whereas melphalan was more effective than temozolomide in another xenograft that had the highest AGT activity. In three other xenografts, there was no significant difference in response between the two chemotherapy agents. This study shows that AGT activity may be useful in predicting the utility of temozolomide-based regional therapy for advanced extremity melanoma tumors. Our observations also point out the limited ability of analysis of the GST/glutathione pathway to predict response to chemotherapies like melphalan whose resistance is primarily mediated through a complexmechanism of detoxification.

Original languageEnglish (US)
Pages (from-to)1492-1500
Number of pages9
JournalMolecular Cancer Therapeutics
Volume6
Issue number5
DOIs
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

temozolomide
Melphalan
Heterografts
Melanoma
Extremities
Glutathione Transferase
Glutathione
Therapeutics
Neoplasms
Drug Therapy
DNA Mismatch Repair
Tumor Burden
Drug Resistance

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Defining regional infusion treatment strategies for extremity melanoma : Comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. / Yoshimoto, Yasunori; Augustine, Christina K.; Yoo, Jin S.; Zipfel, Patricia A.; Selim, M. Angelica; Pruitt, Scott K.; Friedman, Henry S.; Ali-Osman, Francis; Tyler, Douglas.

In: Molecular Cancer Therapeutics, Vol. 6, No. 5, 01.05.2007, p. 1492-1500.

Research output: Contribution to journalArticle

Yoshimoto, Yasunori ; Augustine, Christina K. ; Yoo, Jin S. ; Zipfel, Patricia A. ; Selim, M. Angelica ; Pruitt, Scott K. ; Friedman, Henry S. ; Ali-Osman, Francis ; Tyler, Douglas. / Defining regional infusion treatment strategies for extremity melanoma : Comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 5. pp. 1492-1500.
@article{fa25873b98ab49fd9d8882a9664e4e93,
title = "Defining regional infusion treatment strategies for extremity melanoma: Comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents",
abstract = "Five different human melanoma xenografts were used in a xenograft model of extremity melanoma to evaluate the variability of tumor response to regionally administered melphalan or temozolomide and to determine if various components of pertinent drug resistance pathways for melphalan [glutathione S-transferase (GST)/glutathione] and temozolomide [O6-alkylguanine DNA alkyltranferase (AGT)/mismatch repair (MMR)] could be predictive of tumor response. Xenograft-bearing rats underwent regional isolated limb infusion with either melphalan (90 mg/kg) or temozolomide (2,000 mg/kg). The levels of AGT activity, GST activity, glutathione level, and GST/AGT expression were examined in this group of xenografts and found to be quite heterogeneous. No correlation was identified between melphalan sensitivity and the GST/glutathione cellular detoxification pathway. In contrast, a strong correlation between the levels of AGT activity and percentage increase in tumor volume on day 30 (r =0.88) was noted for tumors treated with temozolomide. Regional therapy with temozolomide was more effective when compared with melphalan for the xenograft with the lowest AGT activity, whereas melphalan was more effective than temozolomide in another xenograft that had the highest AGT activity. In three other xenografts, there was no significant difference in response between the two chemotherapy agents. This study shows that AGT activity may be useful in predicting the utility of temozolomide-based regional therapy for advanced extremity melanoma tumors. Our observations also point out the limited ability of analysis of the GST/glutathione pathway to predict response to chemotherapies like melphalan whose resistance is primarily mediated through a complexmechanism of detoxification.",
author = "Yasunori Yoshimoto and Augustine, {Christina K.} and Yoo, {Jin S.} and Zipfel, {Patricia A.} and Selim, {M. Angelica} and Pruitt, {Scott K.} and Friedman, {Henry S.} and Francis Ali-Osman and Douglas Tyler",
year = "2007",
month = "5",
day = "1",
doi = "10.1158/1535-7163.MCT-06-0718",
language = "English (US)",
volume = "6",
pages = "1492--1500",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Defining regional infusion treatment strategies for extremity melanoma

T2 - Comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents

AU - Yoshimoto, Yasunori

AU - Augustine, Christina K.

AU - Yoo, Jin S.

AU - Zipfel, Patricia A.

AU - Selim, M. Angelica

AU - Pruitt, Scott K.

AU - Friedman, Henry S.

AU - Ali-Osman, Francis

AU - Tyler, Douglas

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Five different human melanoma xenografts were used in a xenograft model of extremity melanoma to evaluate the variability of tumor response to regionally administered melphalan or temozolomide and to determine if various components of pertinent drug resistance pathways for melphalan [glutathione S-transferase (GST)/glutathione] and temozolomide [O6-alkylguanine DNA alkyltranferase (AGT)/mismatch repair (MMR)] could be predictive of tumor response. Xenograft-bearing rats underwent regional isolated limb infusion with either melphalan (90 mg/kg) or temozolomide (2,000 mg/kg). The levels of AGT activity, GST activity, glutathione level, and GST/AGT expression were examined in this group of xenografts and found to be quite heterogeneous. No correlation was identified between melphalan sensitivity and the GST/glutathione cellular detoxification pathway. In contrast, a strong correlation between the levels of AGT activity and percentage increase in tumor volume on day 30 (r =0.88) was noted for tumors treated with temozolomide. Regional therapy with temozolomide was more effective when compared with melphalan for the xenograft with the lowest AGT activity, whereas melphalan was more effective than temozolomide in another xenograft that had the highest AGT activity. In three other xenografts, there was no significant difference in response between the two chemotherapy agents. This study shows that AGT activity may be useful in predicting the utility of temozolomide-based regional therapy for advanced extremity melanoma tumors. Our observations also point out the limited ability of analysis of the GST/glutathione pathway to predict response to chemotherapies like melphalan whose resistance is primarily mediated through a complexmechanism of detoxification.

AB - Five different human melanoma xenografts were used in a xenograft model of extremity melanoma to evaluate the variability of tumor response to regionally administered melphalan or temozolomide and to determine if various components of pertinent drug resistance pathways for melphalan [glutathione S-transferase (GST)/glutathione] and temozolomide [O6-alkylguanine DNA alkyltranferase (AGT)/mismatch repair (MMR)] could be predictive of tumor response. Xenograft-bearing rats underwent regional isolated limb infusion with either melphalan (90 mg/kg) or temozolomide (2,000 mg/kg). The levels of AGT activity, GST activity, glutathione level, and GST/AGT expression were examined in this group of xenografts and found to be quite heterogeneous. No correlation was identified between melphalan sensitivity and the GST/glutathione cellular detoxification pathway. In contrast, a strong correlation between the levels of AGT activity and percentage increase in tumor volume on day 30 (r =0.88) was noted for tumors treated with temozolomide. Regional therapy with temozolomide was more effective when compared with melphalan for the xenograft with the lowest AGT activity, whereas melphalan was more effective than temozolomide in another xenograft that had the highest AGT activity. In three other xenografts, there was no significant difference in response between the two chemotherapy agents. This study shows that AGT activity may be useful in predicting the utility of temozolomide-based regional therapy for advanced extremity melanoma tumors. Our observations also point out the limited ability of analysis of the GST/glutathione pathway to predict response to chemotherapies like melphalan whose resistance is primarily mediated through a complexmechanism of detoxification.

UR - http://www.scopus.com/inward/record.url?scp=34250740979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250740979&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0718

DO - 10.1158/1535-7163.MCT-06-0718

M3 - Article

VL - 6

SP - 1492

EP - 1500

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -